Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Apellis Pharmaceuticals (APLS) EBIAT (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of EBIAT readings, the most recent being -$59.0 million for Q4 2025.

  • For the quarter ending Q4 2025, EBIAT fell 62.16% year-over-year to -$59.0 million, compared with a TTM value of $22.4 million through Dec 2025, up 111.31%, and an annual FY2025 reading of $22.4 million, up 111.31% over the prior year.
  • EBIAT hit -$59.0 million in Q4 2025 for Apellis Pharmaceuticals, down from $215.7 million in the prior quarter.
  • The five-year high for EBIAT was $215.7 million in Q3 2025, with the low at -$219.2 million in Q2 2021.
  • Median EBIAT over the past 5 years was -$130.5 million (2022), compared with a mean of -$105.1 million.
  • The sharpest move saw EBIAT tumbled 289.02% in 2021, then soared 475.52% in 2025.
  • Year by year, EBIAT stood at -$147.9 million in 2021, then dropped by 12.21% to -$166.0 million in 2022, then surged by 46.64% to -$88.6 million in 2023, then soared by 58.96% to -$36.4 million in 2024, then crashed by 62.16% to -$59.0 million in 2025.
  • According to Business Quant data, EBIAT over the past three periods came in at -$59.0 million, $215.7 million, and -$42.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.